Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

ConditionSevere Community-acquired Pneumonia (sCAP)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age19+

SponsorCHOSEOK YOON

About this trial

This study aims to provide high-level evidence for appropriate empirical antibiotic use tailored to the clinical reality in Korea by conducting a randomized controlled trial comparing monotherapy with piperacillin/tazobactam and combination therapy with piperacillin/tazobactam plus a fluoroquinolone in patients with severe community-acquired pneumonia.

Eligibility criteria

Qualifiers

Adult patients aged 19 years or older who visited the emergency department and were hospitalized.

Radiologic evidence of pulmonary infiltration on chest X-ray or chest CT.

Disqualifiers

Transferred from another hospital after >48 hours of hospitalization

Died within 72 hours of hospital admission

Transferred to another hospital within 14 days of admission

Pneumonia occurring after >48 hours of mechanical ventilation, including home ventilators

Trial design

Treatments tested in this trial

Piperacillin/Tazobactam
Piperacillin/tazobactam + Levofloxacin

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

CHOSEOK YOON

Lead sponsor

Seoul Hospital

Sponsor institution

Source ClinicalTrials.gov